stoxline Quote Chart Rank Option Currency Glossary
Revance Therapeutics, Inc. (RVNC)
4.0101  0.2 (5.25%)    07-16 11:37
Open: 3.86
High: 4.08
Volume: 781,108
Pre. Close: 3.81
Low: 3.78
Market Cap: 419(M)
Technical analysis
2024-07-16 11:22:25 AM
Short term     
Mid term     
Targets 6-month :  4.73 1-year :  5.52
Resists First :  4.05 Second :  4.73
Pivot price 2.89
Supports First :  2.96 Second :  2.29
MAs MA(5) :  3.52 MA(20) :  2.85
MA(100) :  3.95 MA(250) :  8.3
MACD MACD :  0.1 Signal :  -0.1
%K %D K(14,3) :  95.6 D(3) :  92.5
RSI RSI(14): 75.7
52-week High :  24.87 Low :  2.29
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ RVNC ] has closed above the upper band by 5.5%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 52.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 3.88 - 3.89 3.89 - 3.91
Low: 3.41 - 3.42 3.42 - 3.44
Close: 3.79 - 3.81 3.81 - 3.83
Company Description

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing DaxibotulinumtoxinA in preclinical trial for the treatment of migraine, as well as a topical program for various indications; and OnabotulinumtoxinA, a biosimilar to BOTOX. The company has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Headline News

Wed, 10 Jul 2024
Revance Therapeutics, Inc. (NASDAQ:RVNC) Receives $11.50 Average Price Target from Analysts - MarketBeat

Tue, 09 Jul 2024
Revance Therapeutics, Inc. (NASDAQ:RVNC) Shares Sold by Principal Financial Group Inc. - Defense World

Thu, 20 Jun 2024
Revance Therapeutics: Problems Mounting Amid Legal And Financial Woes (NASDAQ:RVNC) - Seeking Alpha

Fri, 10 May 2024
Revance Therapeutics, Inc. (NASDAQ:RVNC) Q1 2024 Earnings Call Transcript - Yahoo Finance

Thu, 09 May 2024
Revance Therapeutics, Inc. (RVNC) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance

Thu, 09 May 2024
Revance Therapeutics Inc. (RVNC) Q1 2024 Earnings Call Transcript - Seeking Alpha

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 104 (M)
Shares Float 84 (M)
Held by Insiders 8.5 (%)
Held by Institutions 99.5 (%)
Shares Short 14,350 (K)
Shares Short P.Month 12,490 (K)
Stock Financials
EPS -3.77
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -0.94
Profit Margin -132.2 %
Operating Margin -90.2 %
Return on Assets (ttm) -26.2 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 13.5 %
Gross Profit (p.s.) 0
Sales Per Share 2.29
EBITDA (p.s.) -2.03
Qtrly Earnings Growth 0 %
Operating Cash Flow -213 (M)
Levered Free Cash Flow -143 (M)
Stock Valuations
PE Ratio -1.08
PEG Ratio -0.2
Price to Book value -4.31
Price to Sales 1.76
Price to Cash Flow -1.99
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android